New Whole Animal ELISA for Angiogenic Drug Screening

描述(申请人提供)：这项研究的总体目标是开发一种快速、定量的体内分析格式，用于以斑马鱼为模式生物筛选血管生成药物候选。血管生成是一种重要的生物学过程，涉及多种病理情况，包括癌症、糖尿病视网膜病变、黄斑变性、缺血性心脏病、外周动脉疾病和创面愈合不良。然而，由于缺乏对血管生成生物学基础的了解，以及缺乏检测方法和动物模型，阻碍了药物的开发。斑马鱼试验的一个显著优点是，化合物的治疗潜力是在复杂的生理环境中评估的，比哺乳动物体内生物试验的吞吐量高得多。使用基于细胞的屏幕，这些信息是不可能获得的。公共卫生相关性：血管生成已被证明与几种严重疾病有关，包括糖尿病、癌症、心脏病和黄斑变性。本研究旨在建立一种高通量的斑马鱼体内微孔板定量检测方法，用于评价潜在治疗药物的血管生成效应。

DESCRIPTION (provided by applicant): The overall goal of this research is to develop a rapid, quantitative in vivo assay format for screening angiogenic drug candidates using zebrafish as a model organism. Angiogenesis is well established as a major biological process involved in several pathological conditions, including cancer, diabetic retinopathy, macular degeneration, ischemic heart disease, peripheral arterial disease, and impaired wound healing. However, the lack of understanding of the biological basis of angiogenesis and the lack of assays and animal models have hampered drug development. A significant advantage of the proposed zebrafish assay is that the therapeutic potential of a compound is evaluated in a complex physiological environment with much higher throughput than mammalian in vivo bioassays. Using cell-based screens, this information is impossible to obtain. PUBLIC HEALTH RELEVANCE: Angiogenesis has been shown to be involved in several serious diseases, including diabetes, cancer, heart disease and macular degeneration. This SBIR aims to develop a high throughput quantitative in vivo zebrafish microplate based assay for evaluating angiogenic effects of potential therapeutics.